Efficient and cost-effective removal of endotoxins due to high endotoxin removal rates and protein recovery rates, as well as the scalability of the process.
An advanced endotoxin removal adsorbent with high affinity for endotoxins, enabling efficient removal of up to 99.9% while maintaining protein yield. EtoxiClear is an affinity resin using patented chemically synthesized ligands, capable of removing up to 99.99% of endotoxins, ensuring safe and high-purity products. EtoxiClear offers powerful advantages over traditional endotoxin removal methods, supporting manufacturers in achieving greater efficiency, reliability, and compliance. Comparison of traditional endotoxin removal methods and EtoxiClear: - Excellent endotoxin removal: Outperforms competitors with a reduction rate of 99.99% - High protein recovery: Superior to ion exchange methods with over 90% recovery rate - Wide range of conditions: Usable at pH 4.0 to 8.0 and various salt concentrations - Fast and efficient: Rapid polishing in flow-through mode with PuraBead matrix - Reusable: Regenerated with 0.5 M NaOH, reducing costs over multiple cycles - Versatile: Suitable for antibodies, vaccines, recombinant proteins, and diagnostic reagents.
Inquire About This Product
basic information
Synthetic ligand-based adsorbent Endotoxin binding capacity: >1,000,000 EU/mL adsorbent Operating mode: Flow-through chromatography Over 90% protein recovery rate for a wide range of proteins Column pre-packing: 5 mL to 30 L Operating pH range: pH 4.0 - 8.0 Optimal flow rate: Up to 200 cm/hr Regeneration and depyrogenation: 0.5 M NaOH Storage conditions: 2 - 30°C 20% ethanol : 80% 0.1 M NaCl (v/v) Shelf life: 5 years Designed for regulatory compliance for cGMP manufacturing Comparison with IEX and affinity membranes: High endotoxin removal efficiency (up to 99.99%), high protein recovery rate (>90%)
Price range
Delivery Time
Applications/Examples of results
- Monoclonal antibodies, bispecific antibodies, and other antibody formats - Recombinant proteins and enzymes expressed in bacterial systems like E. coli, maintaining protein integrity and activity - Vaccine production - Plasma-derived proteins - Diagnostic and research applications - Biosimilar manufacturing - Purification of hormones and growth factors - Bioprocess & GMP manufacturing - Biotechnology and academic research
catalog（5）
Download All Catalogs
Company information
Biotage Japan Co., Ltd. is a wholly-owned subsidiary of Biotage AB, which is headquartered in Uppsala, Sweden (BIOT: NASDAQ/OMX Stockholm). Biotage AB has its roots in several venture companies that originated from Uppsala University, a leading science and engineering university in the Nordic region. After undergoing international acquisitions and restructuring throughout the 2000s, it has recently achieved remarkable growth as a global company.